project

CoV-SigN

Identification of novel inhibitors against emerging human coronaviruses SARS-CoV and MERS-CoV from host cellular transcriptionic signatures

French National Research Agency (ANR)

Funder: French National Research Agency (ANR)Project code: ANR-14-CE15-0008
Funder Contribution: 417,638 EUR

Link this project to...

Research outcomes
Deposit your research

Share results

Select content type to share

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=anr_________::602c5b22e1e31c7d687e839e45f98677&type=results"></script>');
-->
</script>

For further information contact us at helpdesk@openaire.eu

Download report

Select content type report to download

Summary
Publications
Research Data
Software
Other Research

Description

In 2012, a novel human coronavirus (MERS-CoV) was identified in the Middle East as the causative agent of a severe acute and/or fatal respiratory syndrome. Since its identification, it has been responsible for 211 laboratory-confirmed cases including 88 deaths. Most cases are sporadic but human-to-human transmission has been documented both in hospital settings and community clusters. Emergence of this new coronavirus in humans raises concerns about a possible widespread outbreak, similar to the one previously caused by SARS-CoV in 2003. Control of such emerging viral pathogens constitutes a major public health issue. However, despite the urgent need for efficie...

Partners

Centre dInfection et dImmunité de Lille, INSTITUT PASTEUR (BP), Laboratoire de Virologie, Virologie et Pathologie Humaines

Summary

Description

Partners

Centre dInfection et dImmunité de Lille, INSTITUT PASTEUR (BP), Laboratoire de Virologie, Virologie et Pathologie Humaines

Any information missing or wrong?Report an Issue